StockNews.AI
TFFP
StockNews.AI
194 days

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

1. TFF Pharmaceuticals plans to delist from Nasdaq by February 16, 2025. 2. The delisting is linked to the company's liquidation and dissolution. 3. No arrangements are made for listing on another exchange. 4. Existing risks include potential impacts from market conditions.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The announcement of delisting and liquidation indicates a significant decline in company viability, reminiscent of past company failures like Enron, leading to loss of investor confidence.

How important is it?

This announcement directly signals the end of operations for TFFP, influencing all stakeholders and potential investors.

Why Long Term?

The company's liquidation process would ensure a prolonged negative impact on its stock and stakeholders.

Related Companies

TFFP
FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for the listing or quotation of its Common Stock on any other exchange, market or quotation medium. The withdrawal of the Common Stock from listing and registration is being undertaken in connection with the planned the liquidation and dissolution of the Company. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding our plans to wind down our operations or other statements not of historical fact. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: the timing, progress and results of our planned wind down; general market conditions; and other risks described in TFF Pharmaceuticals' filings with the Securities and Exchange Commission under the heading "Risk Factors". All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. TFF Pharmaceuticals undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. SOURCE TFF Pharmaceuticals

Related News